{'fraction_non_alphanumeric': 0.016375545851528384, 'fraction_numerical': 0.002183406113537118, 'mean_word_length': 5.280821917808219, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
The emerging landscape of reimbursement of regenerative medicine products in the UK: publications, policies and politics.

AIM
This paper aims to map the trends and analyze key institutional dynamics that constitute the policies for reimbursement of regenerative medicine (RM), especially in the UK.


MATERIALS & METHODS
Two quantitative publications studies using Google Scholar and a qualitative study based on a larger study of 43 semi-structured interviews.


RESULTS
Reimbursement has been a growing topic of publications specific to RM and independent from orphan drugs. Risk-sharing schemes receive attention among others for dealing with RM reimbursement. Trade organizations have been especially involved on RM reimbursement issues and have proposed solutions.


CONCLUSION
The policy and institutional landscape of reimbursement studies in RM is a highly variegated and conflictual one and in its infancy.